Abstract:The PI3 K/Akt signaling pathway controls a wide spectrum of key cellular functions, including cell proliferation and differentiation. The central player Akt is activated by lipid PIP3, which generated by PI3 K and inactivated by tumor suppressor PTEN. Excessive PI3 K/Akt activity or loss of PTEN is often associated with tumorigenesis. Subsequently, full activation of Akt requires its phosphorylation at T308 and S473 by PKD and mTOR, respectively. Recently, we identified a novel protein phosphatase POA as a negative regulator of Akt in a functional genomic screen. Since the PI3 K/Akt signaling is tightly regulated, we hypothesize that POA regulates cellular functions through dephosphorylating Akt. Hence, it is vitally important to investigate the underlying mechanisms and functions for how POA regulates Akt signaling. Objective: (1) To determine whether POA physically interacts with and dephosphorylates Akt, and (2) to investigate how the POA-mediated dephosphorylation terminates the functions of Akt. Methods: We undertook a genome-wide functional genomic screen to identify phosphatases that directly dephosphorylated Akt. Akt phosphorylation in response to insulin or other growth factors was analyzed in normal and tumor cells using immunological methods such as immunoprecipitation (IP), western blotting, immunofluorescence and fluorescence resonance energy transfer (FRET). Effects of POA overexpression and POA knockdown on the level of Akt dephosphorylation were determined by anti-phospho-Akt Western blotting. Real-time PCR and transcriptional analyses of Akt target genes were carried out to determine the functions of POA in regulating Akt responses. POA and its phosphatase-dead mutant were examined for their ability to dephosphorylate Akt, and to affect cell proliferation. Cell proliferation was measured by MTT assays and 3H-thymidine incorporation, and apoptosis detected by caspase cleavage. Muscle differentiation was analyzed in C2C12 myoblasts via myofiber staining. Results: In response to insulin or PDGF, Akt became phosphorylated at T308 and S473. A functional genomic screen identified a novel phosphatase termed POA as a potential Akt phosphatase. Increased expression of POA, but not its phosphatase-dead mutant, abolished growth factor-induced phosphorylation in multiple assays (e.g. IP-Western and FRET). We found that POA could directly interact with Akt in cells and in vitro, and this interaction occurred in the cytoplasm. Importantly, the ability of POA to dephosphorylate Akt was reflected by the functional consequence of POA overexpression or knockdown, which influenced cell proliferation, survival and myoblast differentiation. Conclusion: POA is a novel regulator of the critical PI3 K/Akt signaling pathway. It is conceivable that manipulation of POA activity may provide a platform of intervening the activity of Akt during cancer development.

Obg-Like Atpase 1 Regulates Global Protein Serine/Threonine Phosphorylation In Cancer Cells By Suppressing The Gsk3 Beta-Inhibitor 2-Pp1 Positive Feedback Loop

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism

OLA1 promotes colorectal cancer tumorigenesis by activation of HIF1α/CA9 axis

IDDF2021-ABS-0109 Obg-like ATpase 1 (OLA1) contributes to gastric cancer progression and can be a novel therapeutic target

OLA1 regulates protein synthesis and integrated stress response by inhibiting eIF2 ternary complex formation

Obg-like ATPase 1 exacerbated gemcitabine drug resistance of pancreatic cancer

DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin

Phosphorylation of OGFOD1 by Cell Cycle-Dependent Kinase 7/9 Enhances the Transcriptional Activity of RNA Polymerase II in Breast Cancer Cells

Identification of POA as a Novel Phosphatase of Akt Kinase in a Genome-Wide Functional Genomic Screen

O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth

Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis

Regulation of OLC1 Protein Expression by the Anaphase-Promoting Complex.

O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth

Polo-like kinase 1 (PLK1) O-GlcNAcylation is essential for dividing mammalian cells and inhibits uterine carcinoma

AMOTL2 Inhibits JUN Thr239 Dephosphorylation by Binding PPP2R2A to Suppress the Proliferation in Non-Small Cell Lung Cancer Cells.

SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway

A LATS2 and ALKBH5 positive feedback loop supports their oncogenic roles

The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer

PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor